Squarepoint
TPST icon

Squarepoint’s Tempest Therapeutics TPST Stock Holding History

Squarepoint’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-435
Closed -$102K – 3693
2021
Q1 		$102K Buy
+435
New +$176K ﹤0.01% 2902
2020
Q2 		– Sell
-135
Closed -$139K – 2516
2020
Q1 		$139K Sell
135
-32
-19% -$46.7K ﹤0.01% 1578
2019
Q4 		$220K Buy
167
+73
+78% +$103K ﹤0.01% 2192
2019
Q3 		$130K Buy
94
+41
+77% +$66.2K ﹤0.01% 2156
2019
Q2 		$119K Buy
+53
New +$156K ﹤0.01% 2202
2018
Q1 		– Sell
-30
Closed -$122K – 2147
2017
Q4 		$122K Buy
+30
New +$126K ﹤0.01% 1919
2017
Q1 		– Sell
-7
Closed -$30K – 1911
2016
Q4 		$30K Buy
+7
New +$87.2K ﹤0.01% 1720
2016
Q1 		– Sell
-5
Closed -$142K – 1449
2015
Q4 		$142K Buy
+5
New +$165K 0.02% 1080

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's TPST Position: Q2 2021 in Review

Squarepoint sold out of Tempest Therapeutics (TPST) in Q2 2021, closing a stake of 435 shares — an estimated $102K sold.

Squarepoint first reported a position in TPST in Q4 2015 and held it in 8 quarters. The position peaked at $220K in Q4 2019. 23 funds tracked by Wall St. Rank hold TPST as of Q2 2021.

  • Squarepoint reported no remaining Tempest Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Squarepoint sold 435 Tempest Therapeutics shares in Q2 2021, an estimated $102K.
  • Squarepoint first reported a position in Tempest Therapeutics in Q4 2015 and held it in 8 quarters.
  • Squarepoint's Tempest Therapeutics position peaked at $220K in Q4 2019.
  • 23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2021.

Based on Squarepoint's 13F filing for Q2 2021, filed 16 Aug 2021.